Jump to content

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia


Recommended Posts

http://www.independent.co.uk/news/health/cannabis-extract-marijuana-psychosis-treatment-mental-health-cbd-thc-cannabidiol-kcl-a8111386.html

 

Psychosis is a mental health diagnosis characterised by hallucinated voices or visions, or delusions where patients have strong and unfounded beliefs, for example feeling there is a conspiracy to harm them.

Antipsychotic drugs have been used in treating it for 60 years, but they have limited effectiveness and can have serious side-effects.

Professor Philip McGuire, from King’s College London’s Institute of Psychiatry, Psychology and Neuroscience, was the lead author of the study.

He said conventional drugs acted by blocking biological receptors for mood-altering chemical dopamine.  

“However, dopamine is not the only neurotransmitter whose function is altered in psychosis, and in some patients dopamine function may be relatively normal,” he added.

“We need new classes of treatment that target different neurotransmitter systems.”

This trial found that patients given a CBD treatment saw statistically significant improvements in their psychosis symptoms relative to a group given a placebo.

The 83 patients, from the UK, Romania and Poland, also saw significant improvements in their health and severity of their illness as measured by their therapists.

There were signs of better cognitive performance as well, but this was not statistically significant.

While all the improvements were modest, the patients were still using their antipsychotic medication so it shows CBD treatments can offer additional benefits over and above conventional treatment.

The results are published in the American Journal of Psychiatry today. The paper says: “This is, to our knowledge, the first placebo-controlled trial of CBD in schizophrenia.

“The data indicate that six weeks of treatment adjunctive to antipsychotic medication was associated with significant effects both on positive psychotic symptoms and on the treating clinicians’ impressions of improvement and illness severity.”

Professor McGuire added that larger trials were now needed to confirm these findings in other patient groups.

“Although it is still unclear exactly how CBD works, it acts in a different way to antipsychotic medication, and thus could represent a new class of treatment.

“Moreover, CBD was not associated with significant side effects. This is also potentially important, as patients may be reluctant to take antipsychotic medication because of concerns about side effects.”

https://www.ncbi.nlm.nih.gov/pubmed/29241357

Read the study here.

 

Professor McGuire was singing a different tune about this same study last year.

https://www.medscape.com/viewarticle/862312

 

Lead investigator Philip McGuire, MD, PhD, Department of Psychosis Studies, Institute of Psychiatry Psychology and Neuroscience, Kings College London, United Kingdom, who presented the findings, acknowledged that the improvements with cannabidiol were not dramatic.

However, he told Medscape Medical News: "The way I would look at it is that it's quite hard to see an effect in people who are already being treated with something else.

ih_160421_philip_mcguire_120x156.jpg?int

Dr Philip McGuire

"I would guess that if you didn't have them on antipsychotics, the scope for an improvement would be even greater, because the baseline symptoms would be higher, so it should be easier to show a bigger change."

Noting the lengthy discussion of the data that followed his talk, Dr McGuire said: "Somebody in the audience pointed out that there was a previous trial which compared cannabidiol on its own with an antipsychotic and showed that cannabidiol had the same magnitude of effect as an antipsychotic. That shows that the [effect with] monotherapy is at least as big as an antipsychotic."

The patients were randomly assigned in a double-blind fashion to cannabidiol 1000 mg/day oral solution, 500 mg twice daily, or matched placebo for 6 weeks and were assessed on intention-to- treat analysis.

1 gram CBD per day.

http://alert.psychnews.org/2017/12/cannabidiol-may-be-effective-adjunct-to.html

CBD was well tolerated, and rates of adverse events were similar between the CBD and placebo groups.

 

Please always know where your CBD comes from. Have your CBD tested for purity and accurate dosage / strength.

https://jamanetwork.com/journals/jama/article-abstract/2661569

There is growing consumer demand for cannabidiol (CBD), a constituent of the cannabis plant, due to its purported medicinal benefits for myriad health conditions. Viscous plant derived extracts, suspended in oil, alcohol (tincture), or vaporization liquid, represent most of the retail market for CBD. Discrepancies between federal and state cannabis laws have resulted in inadequate regulation and oversight, leading to inaccurate labeling of some products. To maximize sampling and ensure representativeness of available products, we examined the label accuracy of CBD products sold online, including identification of present but unlabeled cannabinoids.

Read the study here.

Quote

 

Results :

Eighty-four products were purchased and analyzed (from 31 companies).

With respect to CBD, 42.85% of products were under labeled, 26.19% were over labeled, and 30.95% were accurately labeled.

Concentration of unlabeled cannabinoids was generally low; however, THC was detected in 18 of the 84 samples tested, cannabidiolic acid in 13 of the 84 samples tested, and cannabigerol in 2 of the 84 samples tested.

 

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
 Share

  • Similar Content

    • By keith mclaughlin
      On this episode of Let’s be Blunt, Montel speaks with Dr. Jordan Tishler about the importance of patient safety not being lost in the process of adult use legalization. Dr Tishler graduated from both Harvard College and Harvard Medical School, trained at the Brigham and Women’s Hospital, and is currently faculty at both the Brigham and Women’s Hospital and Harvard Medical School. He has spent many years working with the underserved, particularly providing care for veterans. Having treated countless patients harmed by alcohol and drugs, his observation that he had never seen a cannabis overdose led him to delve deeply into the science of cannabis safety and treatment. He is a frequent speaker and author on a variety of topics related to the medical applications of cannabis, and he is the President of the Association of Cannabis Specialists, which aims to educate clinicians, lawmakers, and the industry about best practices and necessary tools for proper patient care.
       
       
    • By keith mclaughlin
      On this episode of Let’s be Blunt, Montel talks with Mark and Christy Zartler. They are parents to twin daughters, one of which, Kara, suffers from Autism and Cerebral Palsy and struggles with severe self-injurious behavior related to her condition. Whole plant cannabis has helped to relieve some of her symptoms when traditional medications didn’t. That wouldn’t be a problem if they lived in a legal medical cannabis state, but they live in Texas. The Zartler’s risk the wrath of law enforcement and Child Protective Services (when Kara was younger) in order to bring their daughter the only medication that brings her relief from her self injurious behavior. They are sharing their story in hopes of helping other families who are coping with similar situations.
       
       
       
    • By keith mclaughlin
      Montel talks with Kentiuky native Jim Higdon on this episode of Let’s Be Blunt. Jim wrote the first non-fiction account of the Cornbread Mafia which tells the story of the biggest domestic marijuana syndicate in American history, which took place in his hometown of Marion County, Kentucky. With the books success, he became a nationally recognized cannabis journalist, covering Kentucky for the Washington Post and cannabis policy for POLITICO. In 2018, he left journalism to co-found Cornbread Hemp.
       
       
    • By keith mclaughlin
      On this episode of Let’s be Blunt, Montel talks with Lisa Quarrell, a mother who lives in East Kilbride, Scotland, who has been tirelessly campaigning for a National Health Service-funded prescription that her son desperately needs. Her 8-year-old son, Cole, was diagnosed with a rare form of severe epilepsy as a baby and suffered up to 20 seizures a day. He had undergone brain surgery and tried 20 different anti-epileptic drugs before before he was prescribed a life-saving cannabis oil which has helped him tremendously. The coronavirus pandemic has made it difficult for her to afford the medication since the fundraising nights she was having were put on hold. She has since been campaigning to have cannabis oil and medications provided and paid for by the NHS but she continues to struggle with the bureaucracy of the Scottish government and NHS Scotland.
       
       
       
    • By keith mclaughlin
      Imagine your child is sick…and then you discover that there is something that can bring them relief…BUT you must break the law in order to access that it, and risk the wrath of law enforcement, and worse yet, the threat of Child Protective Services knocking on your door one day and taking your child from you. Would you take the risk to help your child? The new documentary “Weediatrics”, explores stories of families at the heart of this issue. These brave parents went on camera to tell their stories, in hope of creating a greater understanding and empathy for desperate families across the country in similar situations. On this episode of Let’s Be Blunt, Montel explores this topic with the films producer, Erin O’Hearn.
       
       


×
×
  • Create New...